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Why does cancer risk increase as we age? Frequently attributed to the multi-hit hypothesis and the time
required to accumulate genomic mutations, this question is a matter of ongoing debate. Here, we propose
that the normal decline in oxidative metabolism during aging constitutes an early and important ‘‘hit’’ that
drives tumorigenesis. Central to these metabolic changes are the sirtuins, a family of NAD+-dependent
deacylases that have evolved as coordinators of physiological responses to nutrient intake and energetic
demand. Thus, the modulation of sirtuins might be a fruitful approach to reversing the age-related metabolic
changes that could underlie tumorigenesis.Of all the factors that contribute to cancer, aging is the most
potent (Frank, 2007).More than 60%of all cancers occur in those
aged 65 and above. Why is this so? The most common explana-
tion is the ‘‘multi-hit,’’ or Knudson, hypothesis, which states that
cancer occursmore frequently as we age because time is neces-
sary for cells to accumulate sufficient genetic mutations to push
them over a certain mutagenic threshold and into full-blown
carcinogenesis (Knudson, 1971). What this hypothesis fails to
adequately explain iswhycancer risk is greatly reducedbycalorie
restriction (CR) and physical exercise, and why calorie overload
and a sedentary lifestyle has the opposite effect (Ligibel, 2012).
Restriction of calories to a level 70% of ad libitum intake, for
example, can completely block tumor growth even in situations
where chemical carcinogens would normally evoke a 100%
penetrance of cancer (Lagopoulos and Stalder, 1987; Wallace,
2005). The accumulation of genomic mutations from external
causes such as sunlight and mutagenic compounds might be
expected to occur regardless of diet or physical activity. Here,
we propose that it is not simply the time taken to accumulate
genomic hits that accounts for the increased rate of cancer with
age, but the decline in metabolic homeostasis and gene regula-
tion that occurs normally aswe age. This hypothesis is consistent
with the strong association between cancer prevalence and
type 2 diabetes (Giovannucci et al., 2010), obesity (Renehan
et al., 2008), exercise (Ligibel, 2012), and small molecules that
modulate energy utilization, such as resveratrol (Baur et al.,
2006; Oberdoerffer et al., 2008) and metformin (Lee et al., 2011).
Mitochondrial Homeostasis: A Unifying Link between
Tumorigenesis and the Aging Process?
Recently, it has been established that dysregulated cellular
energetic pathways are not just coincident with tumorigenesis
but are a hallmark of it (Vander Heiden et al., 2009). Known as
the Warburg effect, cancer cells can reprogram carbon meta-
bolism by reducing energy production from oxidative phosphor-
ylation and upregulating glycolysis. This change in mitochondrial
metabolism appears to be advantageous to cancer cells:
reduced oxidative phosphorylation diverts glycolytic and tricar-12 Cancer Cell 25, January 13, 2014 ª2014 Elsevier Inc.boxylic acid (TCA) cycle intermediates into biosynthetic path-
ways including nucleotide biosynthesis and de novo lipogenesis,
which allows the biosynthesis ofmacromolecules and organelles
required for the rapid cell growth and division characteristic of
cancer (Vander Heiden et al., 2009). Moreover, disruption of
mitochondrial homeostasis is usually correlated with increased
reactive oxygen species (ROS), which are not only powerful
damaging agents that can induce mutagenesis but can also
function as signaling molecules that contribute to cancer pro-
gression (Hamanaka and Chandel, 2010).
Though it is clear that metabolic reprogramming is necessary
to support tumor growth, it is less clear what drives the cell to re-
wire its metabolism in the first place. Some clues come from rare
genetic diseases caused by mutations in metabolic regulators.
Peutz-Jegher’s syndrome, for example, is characterized by an
increased risk of cancer in the gastrointestinal tract, pancreas,
cervix, ovary, and breast. The disease is caused by mutations
in Lkb1, a kinase that regulates modulators of theWarburg effect
such as the energy sensor AMP-dependent kinase (AMPK) and
the regulator of growth and proliferation mammalian target of
rapamycin (mTOR; Faubert et al., 2013; Sedelnikova et al.,
2004). Pharmacological agents have also provided clues to the
importance of metabolic reprogramming in cancer. For example,
metformin, a drug that activates AMPK, lowers cancer risk (Lee
et al., 2011) and mTOR inactivation is viewed as an effective
therapy against cancer, with several mTOR inhibitors in clinical
trials (Guertin and Sabatini, 2007).
Another illustrative example is von Hippel Lindau disease,
characterized by tumors predominately in the central nervous
system, retina, kidney, and pancreas. This disease is caused
by a mutation in Vhl, which encodes an E3 ubiquitin ligase that
targets the oxygen-sensitive hypoxia-inducible factor a (HIF-a)
transcriptional regulatory complex for degradation (Maxwell
et al., 1999). Without functional VHL, the tissues of von Hippel
Lindau patients accumulate HIF-1a, which suppresses oxidative
metabolism and promotes aerobic glycolysis, a metabolic
shift commonly observed in cancer cells (Semenza, 2011).
How HIF-1a promotes these changes is largely understood. By
Figure 1. The Geroncogenesis Hypothesis:
Aging-Induced Metabolic Decline as a
Driver of Tumorigenesis
According to the Knudson, or ‘‘multi-hit,’’
hypothesis, cancer occurs more frequently as we
age because time is necessary for cells to acquire
genetic mutations that drive carcinogenesis (indi-
cated by red ‘‘x’’). According to this model, the
shift to oxidative glycolysis, known as theWarburg
effect, occurs subsequent to these early hits. An
alternative possibility is that the natural decline in
oxidative metabolism as we age induces a War-
burg-like metabolic state in normal tissues (indi-
cated by red mitochondria). This increases the
ROS production and sets the metabolic stage for
later mutations to drive tumorigenesis. Low-calo-
rie diets, exercise, and CR mimetic compounds
delay this metabolic shift, thereby reducing the
chance that oncogenic mutations will occur in a
cell with optimal metabolism for tumorigenesis.
The model predicts that CR mimetics could be
used to reverse the metabolic reprogramming of
tumors and even to prevent aging tissues from
undergoing this switch in the first place.
Cancer Cell
Perspectivebinding to specific promoters and sequestering other transcrip-
tional activators such as c-Myc away from promoters, HIF-1a
alters metabolism to favor cell growth (Simon, 2006). HIF-1a
was originally thought to be a survival adaptation by cells within
the hypoxic core of solid tumors, however it is emerging that HIF-
1a is frequently activated in cancers independently of oxygen
availability (Zhong et al., 1999).
Other pathways have been implicated in mediating the meta-
bolic shift during cancer, including the tumor suppressor p53,
which maintains transcription of cytochrome c oxidase subunits
and subsequent functional respiration through synthesis of cyto-
chrome c oxidase 2 (Matoba et al., 2006), and the proto-onco-
gene B-Raf, which regulates mitochondrial biogenesis through
its regulation of peroxisome proliferator-activated receptor g co-
activator 1-a (PGC-1a) and AMPK (Faubert et al., 2013; Haq
et al., 2013). The M2 isoform of pyruvate kinase has also been
implicated as a regulator of the metabolic shift in cancer (Chris-
tofk et al., 2008), although conflicting results have been reported
(Bluemlein et al., 2011).
The mechanisms underlying metabolic reprogramming in
common cancers are still unclear. The prevailing view is that
Warburg-like metabolic changes are genetic in origin, caused
by mutations that accumulate in cells with high levels of genome
instability (Vander Heiden et al., 2009). An alternative possibility
is that the metabolic shift occurs early in a cancer cell lineage
due to epigenetic changes during aging itself (Figure 1). In favor
of this idea, aging in mammals is associated with a reduction in
oxidative phosphorylation and a concomitant increase in aerobicCancer Cell 2glycolysis in many tissues including brain,
liver, and muscle (Bowling et al., 1993;
Hagen et al., 1997; Trounce et al., 1989).
Old animals also have increased lactate
levels both in tissues and in serum, a hall-
mark of increased glycolysis and reduced
oxidative phosphorylation (Ross et al.,
2010). Similarly, type 2 diabetes, a dis-
ease known to accelerate the rate ofmetabolic aging, is associated with a gene expression signature
of glycolytic metabolism similar to that of hypoxia and HIF-1a
accumulation (Ptitsyn et al., 2006) and a decline in oxidative
phosphorylation (Petersen et al., 2004), paralleling the Warburg
effect. Thus, in addition to oncogenic mutations, a shift toward
Warburg metabolism during aging may be one of the ‘‘hits’’
required to push cells into carcinogenesis. This putative mecha-
nism, which we refer to as ‘‘geroncogenesis,’’ may help explain
why the greatest risk of carcinogenesis is age and why inter-
ventions that maintain metabolic health such as metformin and
dietary restriction also prevent cancer.
If the natural decline in oxidative metabolism is a contributor
to tumorigenesis, it is critical we understand why this decline
occurs in the first place. As descendants of symbiotic a-proteo-
bacteria, mitochondria maintain a separate genome that en-
codes tRNA and 13 subunits of the electron transport chain
(Wallace, 2005). The mitochondrial genome is subjected to
constant onslaught from ROS and is highly prone to mutation
(Wallace, 2005). Accumulation of mitochondrial mutations is
considered to be a major contributor to mitochondrial decline
during aging (Trifunovic et al., 2004). Indeed, mice expressing
error-prone mitochondrial DNA polymerase (Polgmut/mut) exhibit
severe electron transport chain deficiencies along with a pre-
mature aging phenotype (Trifunovic et al., 2004). There is also
some evidence that mitochondrial mutations can promote
tumorigenesis: mitochondrial mutations are found in human
cancers, and cybrid cell lines containing mitochondria with a
point mutation in cytochrome oxidase I proliferate into tumors5, January 13, 2014 ª2014 Elsevier Inc. 13
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2005).
Though mitochondrial mutations provide a satisfying explana-
tion for aging, there are some confounding observations. Mice
heterozygous for only one copy of the error-prone mitochondrial
DNA polymerase (Polg+/mut) display a mitochondrial genome
mutation rate over 500 times higher than that of normal aged
mice but, unlike Polgmut/mut homozygous mice, display no
change in lifespan (Vermulst et al., 2007). Also, the redundancy
of having hundreds to thousands of mitochondria present in
each cell, subject to continual fusion, fission, and mitophagy,
allows for dysfunctional mitochondria to be quickly eliminated
(Ono et al., 2001). A high mutation load therefore must be
reached before major metabolic changes become apparent.
Together, these findings suggest that mitochondrial mutations
are but one part of a process that drives the metabolic shift
during aging.
Over the past few years, a role for ‘‘epigenetic’’ alterations in
age-related metabolic decline has become increasingly appreci-
ated. There is evidence, for example, that metabolism becomes
Warburg-like during old age because of a shift in balance be-
tween members of the lactate dehydrogenase complex to favor
the production of lactate, resulting in diversion of pyruvate away
from the TCA cycle and subsequent oxidative phosphorylation
(Ross et al., 2010). The mechanism underlying these changes
remains to be determined, and the importance of these changes
to normal physiology has been the subject of debate (Quistorff
and Grunnet, 2011). Another emerging idea is that the decline
in metabolism during aging is due to a loss in activity of longevity
regulators that are critical for themaintenance of cellular homeo-
stasis. Central to this longevity regulation are the ‘‘sirtuins,’’ a
seven-member family of nicotinamide adenine dinucleotide
(NAD)+-dependent lysine deacylases.
Sirtuins: Relevance for Age-Induced Tumorigenesis and
the Warburg Effect
The founding member of the sirtuin family was Sir2, a yeast tran-
scriptional silencing protein that delays aging in response to low
calorie intake (Lin et al., 2000). In mammals, the seven sirtuins
(SIRT1–SIRT7) play key roles in the regulation of metabolism,
inflammation, DNA repair, circadian rhythms, and aging. Sirtuins
impart their effects largely via their catalytic activity, removing
acyl-lysine moieties from proteins via a multi-step reaction that
consumes NAD+ (Feldman et al., 2012). The number of lysine
modifications that are known to be removed by sirtuins has
grown in recent years to include acetyl-, succinyl-, malonyl-,
and long-chain fatty acyl groups. Decreased activity of sirtuin
family members during aging, especially SIRT1, SIRT3, and
SIRT6, has been strongly implicated in the susceptibility of
organs to aging and age-related diseases (Baur et al., 2006;
Brown et al., 2013; Kanfi et al., 2012). A major cause of the
decline in sirtuin activity is a decrease in NAD+ levels with age,
a decline that is accelerated by obesity and counteracted by
CR and physical activity (Koltai et al., 2010; Yang et al., 2007).
Over the past few years, it has become increasingly clear that
the maintenance of sirtuin activity is likely to be critical for pre-
venting tumorigenesis and slowing tumor growth in many tis-
sues, but there are also studies indicating the opposite (Table 1).
Mechanisms of tumor suppression by sirtuins initially focused14 Cancer Cell 25, January 13, 2014 ª2014 Elsevier Inc.on their ability to halt the cell cycle, inactivate oncogenic
transcription factors, and promote DNA repair, but more recent
studies have shown that their effects on energy metabolism
may be equal, if not more important, for tumor suppression
(Figure 2; Csibi et al., 2013; Finley et al., 2011; Firestein et al.,
2008; Herranz et al., 2010; Jeong et al., 2013; Kim et al., 2010;
Narayan et al., 2012; Oberdoerffer et al., 2008; Sebastia´n et al.,
2012; Serrano et al., 2013). The sirtuin with the strongest known
influence on tumorigenesis is SIRT3, a mitochondrial enzyme
that regulates ROS production and enzymes that facilitate the
TCA cycle, oxidative phosphorylation, and fatty acid metabolism
(Finley et al., 2011; Hirschey et al., 2010). Deletion of Sirt3 results
in chromosomal instability in vitro and causes spontaneous
mammary tumorigenesis in mice, with metabolic changes that
include increased glucose uptake, decreased ATP generation,
and ametabolic reprogramming that parallels theWarburg effect
(Kim et al., 2010). Thismetabolic switch ismediated by increased
ROS that stabilize HIF-1a, thereby upregulating glycolysis and
decreasing mitochondrial respiration (Bell et al., 2011; Finley
et al., 2011). In one study, Sirt3 was deleted in 30% of breast
cancer samples (Finley et al., 2011). Though these data are
compelling, the tumor-suppressive role of SIRT3 is not clear
cut: other studies indicate that Sirt3 is overexpressed in breast
cancer compared to healthy mammary tissue (Alhazzazi et al.,
2011b; Ashraf et al., 2006) and knockdown of this protein
reduces tumor burden in an oral cancer model (Alhazzazi et al.,
2011a).
Another sirtuin implicated in tumorigenesis is SIRT6, a
chromatin-associated enzyme with deacetylase and long-chain
deacylase activities. Sirt6 deletion increases HIF-1a and c-Myc
transcriptional activity, with a corresponding upregulation of
glycolysis (Sebastia´n et al., 2012; Zhong et al., 2010). Remark-
ably, knockdown of Sirt6 in otherwise normal mouse embryonic
fibroblasts (MEFs) transforms them, independently of activation
of known oncogenes (Sebastia´n et al., 2012). Although SIRT6
is required for genomic stability (Mostoslavsky et al., 2006),
re-introduction of Sirt6 into knockout MEF cells in which
genomic instability might already have been expected to take
place represses tumor formation, effectively ruling out mutations
as a cause (Sebastia´n et al., 2012). These findings further under-
score the idea that metabolic alterations are required, if not
sufficient, to induce tumor growth.
SIRT1, a nuclear sirtuin, was the first family member shown
to act as a tumor suppressor. Pharmacological activation or ge-
netic overexpression of Sirt1 increases genomic stability in cells
treated with DNA-damaging agents, delays lymphoma, and
improves the survival of irradiated p53+/ mice (Oberdoerffer
et al., 2008), while Sirt1 deletion has the opposite effect (Wang
et al., 2008). By localizing to sites of DNA damage and facilitating
the recruitment of DNA repair factors such as histone deacety-
lase 1, Rad51, and Nbs1, SIRT1 plays a key role in promoting
genome stability, a function that declines with age (Dobbin
et al., 2013; Oberdoerffer et al., 2008). One of the strongest
effects of SIRT1 in vivo is its ability to protect mice in the hetero-
geneous diethylnitrosamine-induced model of hepatocellular
carcinoma (Herranz et al., 2010), potentially by suppressing
inflammatory responses in this organ. SIRT1 can also suppress
tumorigenesis by negatively regulating oncogenic transcription
factors, including b-catenin (Firestein et al., 2008) and c-Myc
Table 1. Evidence for Sirtuins as Tumor Suppressors or Promoters
Sirtuin Examples of Tumor Suppression Examples of Tumor Promotion
SIRT1 Sirt1 overexpression suppresses hepatocellular carcinoma
in diethylnitrosamine-treated mice (Herranz et al., 2010)
small molecule inhibition of SIRT1 reduces growth of transplanted
Bcr-Abl chronic myeloid leukemia cells (Li et al., 2012)
Sirt1 overexpression suppresses colon cancer in ApcMin/+
mice (Firestein et al., 2008)
Sirt1 overexpression and resveratrol suppress lymphoma
in irradiated p53+/ mice (Oberdoerffer et al., 2008)
SIRT1 inhibits the tumor suppressor p53 (Luo et al., 2001)
tumorigenesis in Sirt1 knockout mice (Wang et al., 2008) Sirt1 overexpression promotes thyroid tumorigenesis in Pten+/ mice
(Herranz et al., 2013)
SIRT1 promotes degradation of c-Myc; overexpression
represses colony formation in HO15 and Myc3 Rat1 cells
(Yuan et al., 2009)
SIRT1 promotes stabilization of c-Myc; partial reduction in
proliferation of Myc transformed U937 monoblasts in vitro
(Menssen et al., 2012)
SIRT1 allosteric activator resveratrol suppresses
DMBA-induced skin cancer (Jang et al., 1997)
Sirt1 overexpression increases tumor growth in orthotopic xenografted
hereditary colon cancer cell lines (Portmann et al., 2013)
SIRT2 Sirt2 deletion causes spontaneous tumorigenesis in
mice (Narayan et al., 2012)
SIRT2 inhibition reduces proliferation of BE(2)-C and MiaPaca cell lines
in vitro (Liu et al., 2013)
Sirt2 deletion causes spontaneous tumorigenesis in
mice (Serrano et al., 2013)
SIRT3 Sirt3 knockdown increases, and overexpression reduces
tumor size in orthotopic xenografts (Bell et al., 2011)
Sirt3 knockdown increases tumor burden in orthotopic xenograft
tumor model (Alhazzazi et al., 2011a)
Increased soft agar colony formation in knockout MEF cells,
Sirt3 deletion in 30% of breast cancers (Finley et al., 2011)
increased Sirt3 expression in node positive breast cancer (Ashraf
et al., 2006)
tumor formation in Myc, Ras transformed immortalized
MEF cells (Kim et al., 2010)
SIRT4 decreased tumor growth in orthotopic immortalized Tsc2/
MEF cells overexpressing Sirt4 (Csibi et al., 2013)
no strong evidence
increased tumor growth in immortalized Sirt4/ MEF cells
(Jeong et al., 2013)
SIRT6 increased tumorigenesis in immortalized Sirt6/ MEF cells
(Sebastia´n et al., 2012)
no strong evidence
Sirt6 overexpression induces apoptosis in cancer cells but
not normal cells in vitro (Van Meter et al., 2011)
SIRT7 SIRT7 negatively regulates HIF-1a and HIF-2a (Hubbi et al.,
2013), potentially underlying aspects of the Warburg effect
decreased growth of U251 xenografts with Sirt7 knockdown (Barber
et al., 2012)
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reported (Menssen et al., 2012).
Similar to SIRT3 and SIRT6, SIRT1 might influence tumorigen-
esis, not only through its ability to regulate genomic stability, but
also by regulating cellular metabolism. SIRT1 regulates the tran-
scriptional activity of HIF-1a (Lim et al., 2010), which is also an
important regulator of the Warburg effect as well as angiogen-
esis and metastasis. SIRT1 also deacetylates and activates liver
kinase B1 (LKB1; Lan et al., 2008), a known tumor suppressor
that regulates mTOR and AMPK (Sedelnikova et al., 2004). Inter-
estingly, the effects of SIRT1 on tumorigenesis are context
dependent. For example, inhibition of SIRT1 improves the effi-
cacy of a chemotherapeutic agent (Imatinib) against chronic
myeloid leukemia (Li et al., 2012) and blocks the proliferation of
hepatocellular carcinoma cell lines in vitro and in a xenograft
model (Portmann et al., 2013). Conversely, Sirt1 overexpression
can accelerate thyroid cancers in vivo (Herranz et al., 2013).
These latter findings likely reflect the ability of SIRT1 to inhibit
the tumor suppressor p53, which promotes survival under situa-
tions of cell stress (Luo et al., 2001).There is evidence that SIRT2, the cytosolic sirtuin, is also a
tumor suppressor. Deletion of Sirt2 results in spontaneous
tumorigenesis in the liver and accelerates the 7,12-dimethyl-
benz(a)anthracene (DMBA)/12-O-tetradecanoylphorbol-13-ac-
etate model of skin cancer (Narayan et al., 2012; Serrano et al.,
2013). One mechanism is likely to be cell cycle control, as
SIRT2 deacetylates and regulates CDH1 and CDC20, members
of the anaphase-promoting complex (Narayan et al., 2012).
Moreover, SIRT2 transiently migrates to the nucleus during
mitosis (North and Verdin, 2007), where it modulates the activity
of the methyltransferase PR-Set7, resulting in H4K20 methyl-
ation (Serrano et al., 2013), a chromatin mark involved in
genomic stability (Oda et al., 2009). Although primarily studied
in the context of its cytosolic regulation of cell cycle, one inter-
esting possibility is that SIRT2 influences mitochondrial function
and the Warburg effect by deacetylating CDH1, a protein that
limits glycolysis and proliferation of cancer cell lines through
ubiquitination and degradation of the glycolysis-promoting
enzyme 6-phosphofructo-2-kinase (Almeida et al., 2010). Again,
the data are not clear cut; an in vitro study found that SIRT2Cancer Cell 25, January 13, 2014 ª2014 Elsevier Inc. 15
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Figure 2. Sirtuins Are Central to Metabolic Reprogramming during
Aging and Cancer
Sirtuins control key nodes in the regulation of glycolysis (HIF-1a, HIF-2a, and
c-Myc) and oxidative phosphorylation (PGC-1a, LKB1, and TCA enzymes). A
decline in the activity of the sirtuin family of enzymes in old age is hypothesized
to lead to a shift toward a predominantly glycolytic, Warburg-like metabolism
that could contribute to the exponential increase in cancer susceptibility during
aging.
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cell growth through stabilization of Myc oncoproteins (Liu et al.,
2013).
Recently, two other sirtuins, SIRT4 and SIRT7, have also
been implicated in the regulation of tumorigenesis. The mito-
chondrial sirtuin SIRT4 promotes metabolic reprogramming
by facilitating the cataplerotic diversion of carbons from the
TCA cycle to aerobic glycolysis and lactate generation, forcing
cancer cells to rely on glutamine for replenishment of the TCA
cycle (Csibi et al., 2013; Jeong et al., 2013). Upon DNA dam-
age, Sirt4 expression is upregulated, leading to a repression
of glutamine metabolism through its inhibition of glutamate
dehydrogenase, which converts glutamate into a-ketoglutarate
(Csibi et al., 2013; Jeong et al., 2013). This shift prevents the
cell from upregulating nonessential biosynthetic pathways
and undergoing premature cellular division prior to genomic
repair (Csibi et al., 2013; Jeong et al., 2013). The nucleolar
sirtuin, SIRT7, may also regulate cellular metabolism by
negatively regulating HIF-1a and HIF-2a (Hubbi et al., 2013),
potentially underlying the Warburg effect. The role of SIRT7
in tumorigenesis, however, also seems context dependent:
SIRT7 may help maintain a pro-oncogenic phenotype by
interacting with the transcription factor ELK4 and deacetylating
H3-K18, a modification that promotes tumor growth (Barber
et al., 2012).
Therapeutic Strategies to Combat Age-Induced
Tumorigenesis
Mutations that give rise to cancer are essentially irreversible.
However, if age-related metabolic changes are an early driver
of tumorigenesis, molecules that prevent and reverse metabolic
aging may be useful as cancer therapies. Indeed, molecules16 Cancer Cell 25, January 13, 2014 ª2014 Elsevier Inc.such as metformin and HIF-1a inhibitors in development show
promise as anticancer agents (Onnis et al., 2009). Given the
key role of sirtuins in tumorigenesis, it is feasible that lifestyle
interventions and/or small molecules that activate sirtuins could
induce a youthful metabolic state and serve to prevent and treat
cancer. Direct SIRT1 activators that work by allosteric mecha-
nisms (Hubbard et al., 2013) have been developed. These
molecules are in human clinical trials to treat metabolic and
inflammatory diseases, but they are not yet under investigation
as chemotherapy adjuncts.
An alternative approach to activating sirtuins, one that raises
the activity of the entire family of enzymes, is to exploit their com-
mon requirement for NAD+. Increasing NAD+ levels has been
shown to protect mice from metabolic decline in mouse models
of obesity and aging (Canto´ et al., 2012; Escande et al., 2013;
Yoshino et al., 2011), but it is not yet considered a viable strategy
for cancer, in part because raising overall NAD+ levels is not
without risks. As described above, there is evidence that
SIRT1 and SIRT7 may promote the growth of cancers. It is also
important to consider the role of NAD+ as a redox carrier that
is essential to glycolysis, which cancer cells heavily rely upon.
Another consideration is the fact that raising NAD+ may not be
as simple as it sounds. NAD+ is compartmentalized into cyto-
solic, nuclear, and mitochondrial pools (Nikiforov et al., 2011),
and it is unclear what degree of flux exists between these pools
and whether a particular pool of NAD+ influences the Warburg
effect and tumorigenesis.
Some researchers have taken the opposite approach, seizing
upon the fact that NAD+ is an essential redox carrier for glycol-
ysis and cancer cell viability. FK866, a small molecule inhibitor
of the NAD+ recycling enzyme Nampt, has strong antiproli-
ferative effects in cancer cells and has entered clinical trials
(Hasmann and Schemainda, 2003). Of course, NAD+ depletion
can also be toxic to normal cells. If the approach does prove
effective as a chemotherapeutic strategy, it will be important to
optimize dosing to avoid toxicity to noncancerous cell types.
Clearly, more work is required to determine whether raising or
decreasing NAD+ levels will be beneficial for the treatment of
cancer in humans and which specific pools of NAD+ influence
tumorigenesis.
Conclusions and Future Perspectives
While the ‘‘multi-hit’’ concept of oncogenic DNA mutations has
dominated cancer biology for the past few decades, aberrant
tumor metabolism and disruption of mitochondrial homeostasis
are emerging as key drivers of both initiation and progression of
cancer. Metabolic reprogramming is currently viewed as a late
stage of tumorigenesis, the result of mutations that accumulate
over time. Here, we propose that one of the early drivers of
tumorigenesis is aging-induced dysregulation of mitochondrial
metabolism. This may be driven, in part, by an age-related
decline in NAD+ and sirtuin activity. These metabolic changes
likely occur independently of, and may even precede, genomic
lesions, acting as an early ‘‘hit’’ that pushes cells toward com-
plete cellular transformation. If seen though this lens, aging
induces a gradual reprogramming of metabolism toward a ‘‘can-
cer-like’’ state, a transformation that is accelerated by increased
calorie intake and a sedentary lifestyle and that is counteracted
by low-calorie diets and exercise. This may explain why diet,
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Perspectiveexercise, and CR mimetics, which alter the pace of metabolic
aging, strongly influence cancer susceptibility (Baur et al.,
2006; Lee et al., 2011; Ligibel, 2012; Oberdoerffer et al., 2008;
Renehan et al., 2008). If this hypothesis holds true, there may
come a day when lifestyle interventions along with CR mimetics
are used to reverse the metabolic reprogramming of tumors and
even to prevent aging tissues from undergoing the metabolic
switch in the first place.
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